Why is early engagement with EMA, payers, KOLs, and patient groups so important?
Welcome to the Expert Q&A series
Where AzurBio’s industry veterans distill decades of experience into the very information you need: critical knowledge to understand European markets and avoid common pitfalls that derail market entry strategies.
Key takeaway
Early stakeholder engagement in Europe is your strategic insurance policy. By proactively connecting with EMA, payers, KOLs, and patient groups before Phase 3, you transform potential roadblocks into guided pathways. This approach prevents costly late-stage surprises, aligns your development program with both regulatory and market expectations, and builds the advocacy network essential for successful EU market access. The upfront investment in stakeholder relationships pays dividends by reducing regulatory risk and accelerating post-approval adoption.

Sophie Lamaison
Associate Director, Regulatory Affairs
15 years of experience in the pharmaceutical industry and consultancy, primarily focused on the European regulatory environment. She holds a Pharm.D. and a master’s degree in EU Regulatory Affairs. She has worked across multiple therapeutic areas, including oncology, rare diseases, women’s health, radiopharmaceuticals, and dermatology.
Early engagement with key stakeholders in Europe can make or break your strategy. Proactive communication and seeking advice early yield multiple benefits:
Regulatory Scientific Advice
The EMA and national Health Agencies offer Scientific Advice meetings at any development stage to guide sponsors on optimal study design and evidence generation. Taking advantage of this early scientific advice helps ensure your trials meet EU expectations to minimize the risk that “a major objection” arises during review.
In other words, by consulting EMA/national Health Agencies early on (even in preclinical or Phase 1), you can align your development plan with European standards and avoid conducting studies that won’t satisfy EU regulators. Remember, following advice isn’t legally binding, but it significantly de-risks your path.
Payer and HTA Input
Europe’s payers and Health Technology Assessment (HTA) bodies (like NICE in the UK, HAS in France, G-BA in Germany) heavily influence if and how your drug will be reimbursed. Engaging them early, even before Phase 3, can align your trial endpoints and data collection with the outcomes that determine value in their eyes.
The EU now even supports parallel consultations where developers get joint feedback from EMA and HTA bodies simultaneously, including Joint Scientific Assessment (JSC) and Joint Clinical Assessment (JCA). Early payer advice helps you design trials that capture real-world effectiveness and cost-effectiveness data needed for reimbursement. This prevents a scenario where you have an approved drug that payers deem unconvincing on value.
Key Opinion Leaders (KOLs)
Engaging European clinical experts and medical societies in your therapeutic area provides insights into local standards of care and unmet needs. KOLs can advise on endpoints or comparator choices that will resonate with EU regulators and clinicians. They may also become advocates for your therapy, which is valuable for both regulatory review (expert testimonials) and later uptake. Involving KOLs early (e.g. via advisory boards or including European investigators in Phase 3 trials) builds credibility.
Patient Associations
Similarly, patient advocacy groups in Europe can offer perspective on meaningful outcomes and support recruitment. Their buy-in can later bolster your case in front of regulators and HTA agencies, as patient voices are increasingly influential in Europe.
Avoiding Costly Redesigns
Early stakeholder engagement ensures you “build quality in” to your development program. For example, a company might discover via EMA advice that a certain quality (CMC) study or a specific clinical endpoint is required. Learning this at Phase 2 is far better than finding out at filing. Likewise, payer input might prompt collecting quality-of-life data or starting a patient registry early on. These adjustments are much harder (or impossible) to retrofit later. Engaging stakeholders by Phase 2 at the latest gives time to pivot and incorporate their feedback.
In short, engaging early with EMA, payers, KOLs, and patients creates a roadmap that integrates regulatory and market needs. As one expert insight notes: “Engage early with local decision-makers, including HTA bodies, payers, and KOLs. Understanding local requirements can help tailor your value proposition for each market.” By investing in these relationships and advice early, you set your program up for smoother sailing through EU approvals and access.